The Guide to Pharmaceutical Pricing & Reimbursement Systems: Western Europe : Market Research Report

The Guide to Pharmaceutical Pricing & Reimbursement Systems: Western Europe

Published: Nov. 1, 2005 - 245 Pages

Austria
Belgium
Denmark
Finland
France
Germany
Greece
Ireland
Italy
Netherlands
Norway
Portugal
Spain
Sweden
Switzerland
United Kingdom
List of Figures: Austrian healthcare financing by category in 2002 (€m); Austrian pharmaceutical market 2001-2003 (€m at consumer price level)*; Health spending in Austria; Increase in pharmaceutical sales of reimbursed drugs Austria; Pharmaceutical price regulation classification in Austria; Number of medicinal products according to classification (1 January 2005); The registration to reimbursement structure for pharmaceuticals in Austria; Pharmaceutical hospital sales in Austria; Austrian OTC sales; Patient co-payments 2001-2005 (€); Growth of generics market in Austria (2000-2005); Wholesale pharmacy margins (2005); Pharmacy margins for purchasers who receive preferential treatment; Pharmacy margins for private customers; Price structure of medicines in Austria in 2003; Price build-up of pharmaceuticals in Austria - 2005; Changes to the pharmaceutical pricing and reimbursement system in Austria (1995-2005); Summary of pharmaceutical cost-containment measures in Austria; Healthcare budget in Belgium; Administrative procedures for pharmaceutical pricing and reimbursement; Reimbursement rates by drug category in Belgium; Drug pricing and reimbursement timeline; Healthcare expenditure by drug category; NCE reimbursement premiums in Belgium (2000); Refused registrations in Chapter I; Summary of patient co-payment criteria in Belgium; The Maximum A Facturer Cap; Price breakdown of pharmaceuticals according to consumer price; Average price build-up of pharmaceuticals; Changes to the drug price and reimbursement system in Belgium (1992-2006); Summary of pharmaceutical cost-containment measures in Belgium; Danish pharmaceutical market 2002-2004 (€m at consumer price level)*; Sales pharmaceutical specialties, 2001-2005 (pharmacy purchase prices; DKKm); Number of active substances, medicinal products and packs, on the Danish market 2000-2004; Price development of pharmaceuticals; Reimbursement, co-payment and turnover of pharmaceuticals sold to individuals divided by reimbursement types in the third quarter of 2004; Ongoing medicine reimbursement re-assessment procedure; Sales of medicinal products in the hospital sector 2000-2004 (DKKm); Annual patient reimbursement levels for prescription medicines; Permitted price variation for generic substitution in Denmark; Pharmacy margins in Denmark - 2002; Price build-up of pharmaceuticals in Denmark - 2005; Price build up of pharmaceuticals, EU average vs. Denmark; Parallel imports in Denmark; Changes to the drug price and reimbursement system in Denmark (1991-2005); Summary of pharmaceutical cost-containment measures in Denmark; Danish pharmaceutical market 2002-2004 (€m at consumer price level)*; Sales pharmaceutical specialties, 2001-2005 (pharmacy purchase prices; DKKm); Number of active substances, medicinal products and packs, on the Danish market 2000-2004; Price development of pharmaceuticals; Reimbursement, co-payment and turnover of pharmaceuticals sold to individuals divided by reimbursement types in the third quarter of 2004; Ongoing medicine reimbursement re-assessment procedure; Sales of medicinal products in the hospital sector 2000-2004 (DKKm); Annual patient reimbursement levels for prescription medicines; Permitted price variation for generic substitution in Denmark; Pharmacy margins in Denmark - 2002; Price build-up of pharmaceuticals in Denmark - 2005; Price build up of pharmaceuticals, EU average vs. Denmark; Parallel imports in Denmark; Changes to the drug price and reimbursement system in Denmark (1991-2005); Summary of pharmaceutical cost-containment measures in Denmark; Pharmaceutical sales at consumer prices in Finland, 2004; Breakdown of drug sales in 2003; Wholesale price index for all medicines, prescription medicines and self-care medicines compared to the consumer price index, 1998-2003; Wholesale price and special reimbursement status application process; Medicine reimbursement paid by the SII, 2003; Most significant diseases entitling the patient to special reimbursement of medicine costs, 2003; Most significant diseases entitling the patient to special refunds and average cost per recipient, 2004; Drugs granted special reimbursement status in 2004; First year of generic substitution in Finland (April 2003-March 2004); Pharmacy price bands in Finland - 2003; State-imposed pharmacy fees in Finland - 2003; Figure.12 Price build-up of pharmaceuticals in Finland, 2004; Changes to the drug price and reimbursement system in Finland (1990-2005); Summary of pharmaceutical cost-containment measures in Finland; Pharmaceutical sales at consumer prices in Finland, 2004; Breakdown of drug sales in 2003; Wholesale price index for all medicines, prescription medicines and self-care medicines compared to the consumer price index, 1998-2003; Wholesale price and special reimbursement status application process; Medicine reimbursement paid by the SII, 2003; Most significant diseases entitling the patient to special reimbursement of medicine costs, 2003; Most significant diseases entitling the patient to special refunds and average cost per recipient, 2004; Drugs granted special reimbursement status in 2004; First year of generic substitution in Finland (April 2003-March 2004); Pharmacy price bands in Finland - 2003; State-imposed pharmacy fees in Finland - 2003; Price build-up of pharmaceuticals in Finland, 2004; hanges to the drug price and reimbursement system in Finland (1990-2005); Summary of pharmaceutical cost-containment measures in Finland; European average prices in relation to France; Payback system for companies that have not signed conventions with the CEPS; Fee exemptions per pharmaco-therapeutic aggregate; Tax on promotional spend of pharmaceuticals; Share of generics as a percentage of all medicines sold 1999-2003; Directory of generics as percentage of the market for reimbursable products; Wholesaler and pharmacy margins 2005; Price build-up for an average €10 non-reimbursable and reimbursable medicinal; Changes to the drug price and reimbursement system in France (1990-2004); Summary of pharmaceutical cost-containment measures in France; Pharmaceutical industry in Germany (2003): figures and facts; Pharmaceutical sales per capita (2002 in US$ adjusted for purchasing power); Expenditures in statutory health insurance system (2003); Sales and packages sold through pharmacies (2003); Pharmaceutical prices: an international comparison (2003); Regulatory measures and attractiveness of German generics market (2001); Pharmacy margins in Germany; Price build-up of lower priced pharmaceuticals in Germany - 2004; Price build-up of higher priced pharmaceuticals in Germany - 2004; Price structure of prescription medicines in Germany vs. Europe - 2001; Parallel Imports in the pharmacy market (at manufacturer's prices); Changes to the drug price and reimbursement system in Germany (1993-2004); Summary of pharmaceutical cost-containment measures in Germany; Pharmaceutical industry in Germany (2003): figures and facts; Pharmaceutical sales per capita (2002 in US$ adjusted for purchasing power); Expenditures in statutory health insurance system (2003); Sales and packages sold through pharmacies (2003); Pharmaceutical prices: an international comparison (2003); Regulatory measures and attractiveness of German generics market (2001); Pharmacy margins in Germany; Price build-up of lower priced pharmaceuticals in Germany - 2004; Price build-up of higher priced pharmaceuticals in Germany - 2004; Price structure of prescription medicines in Germany vs. Europe - 2001; Parallel Imports in the pharmacy market (at manufacturer's prices); Changes to the drug price and reimbursement system in Germany (1993-2004); Summary of pharmaceutical cost-containment measures in Germany; Healthcare expenditure as proportion of GDP in Greece; Healthcare spending in Greece; Healthcare expenditure in Greece; Pharmaceutical sales in Greece; Pharmaceutical spending in Greece; Generic and innovative sales in Greece at wholesale price; Price build-up for imports of most EU medicinal products in Greece; Price structure of some imported EU medicinal products in Greece; Parallel trade at consumer prices in Greece; Summary of pharmaceutical cost-containment measures in Greece; Publicly funded, privately funded and total health expenditure (percentage of GDP); Ireland compared to the OECD member countries average, 2002; Public Expenditure on Health in Ireland, 1998-2004; Growth in state expenditure on medicines in Ireland, 1998-2003; GMS scheme expenditure in Ireland, 1997-2003; Payments by the General Medical Services (Payments) Board (€m); Long term illness scheme expenditure 1997-2003; Drug payment scheme expenditure in Ireland, 1997-2003; High tech drugs scheme expenditure in Ireland, 1997-2003; Price composition for oral medicinal products in Ireland, 2005; Price composition for non-oral medicinal products in Ireland, 2005; Summary of pharmaceutical cost-containment measures in Ireland; SSN pharmaceutical expenditure: comparison between 2003 and 2004; Pharmaceutical expenditure; first 9 months of 2004; Territorial pharmaceutical expenditure and consumption volume: comparison between 2002 and 2003; Retail sales of OTC healthcare by sector: value 2001-2003; Market of SSN reimbursed products (net expenditure); Generics market evolution; Price build-up for medicinal products in Italy - up to June 2004; A decade of changes to the drug price and reimbursement system in Italy (1994 onwards); Summary of pharmaceutical cost-containment measures in Italy; Useful contacts; Pharmaceutical market in the Netherlands (€m consumer price level); Top ten drugs by expenditure in The Netherlands, 2003; Price composition for medicinal products in The Netherlands - 2004; Price build-up of medicines, Netherlands vs. EU average; Summary of Pharmaceutical Cost-Containment Measures in The Netherlands; Who pays for pharmaceuticals in Norway; Price build up of non-prescription medicines - 2003; Co-payment conditions and calculations for generic substitution - 2004; Price build-up for non-prescription medicines in Norway - 2003; Changes to the drug price and reimbursement system in Norway (1990-2002); Summary of pharmaceutical cost-containment measures in Norway; Pharmaceutical Market in Portugal 2002-2003 - €m; Annual prices revision of medicinal products 1995-2002; Reimbursement criteria in Portugal; Price build-up for non-prescription medicines in Portugal - 2004; Patient co-payment system; Generic market 2000-2004; Portuguese generic market 2000-2004; Price structure of prescription medicines in Portugal vs. Europe - 2001; Changes to the drug price and reimbursement system in Portugal (1992-2005); Summary of pharmaceutical cost-containment measures in Portugal; Weighted average price of pharmaceuticals in main European Union countries 2000 & 2001 (Retail price, inc. VAT); Pharmacy margins according to monthly public reimbursed totals; Price structure of prescription medicines in Spain vs. Europe - 2001; Price build-up for medicines costing €89.62 or less - 2005; Pharmaceutical distribution margins 2005; New measures introduced in 2005 through the RD 2.402/2004 and the new strategic pharmaceutical policy plan; Summary of pharmaceutical cost-containment measures in Spain; Sweden, Pharmaceutical market in €m at pharmacy purchasing price* - 2001 to 2003; Co-payment and reimbursement levels for prescribed medicines in Sweden; Pharmacy mark-ups for dispensing in Sweden (SEK); Price build-up for medicines in Sweden in 2004; Changes to the drug price and reimbursement system in Sweden (1990-2003); Summary of pharmaceutical cost-containment measures in Sweden; Pharmaceutical market by type (by manufacturers' prices) in Switzerland - 2002; Pharmaceutical market in Switzerland (by sales of medicines) in 2003; Healthcare expenditure by categories (as % of total expenditure on healthcare); Breakdown of the pharmaceutical market in Switzerland; Healthcare resources (per 1000 Population) - Switzerland vs. EU (2002); Price build-up for medicines in Switzerland, List C and D products - 2004; Price structure of prescription medicines in Switzerland vs. Europe - 2001; Pharmaceutical margins in Switzerland; Sales of non-prescription drugs in Switzerland by distribution channel - 1999; A decade of changes to the drug price and reimbursement system in Switzerland (1994 onwards); Summary of pharmaceutical cost-containment measures in Switzerland; NHS expenditure on medicines per person in the UK; Definitions of prescribing costs; PPA payments to contractors; Reimbursement of items on an FP10 Prescription Form; Example of timing of reimbursement by PPA to pharmacists; The UK drug tariff for generic medicines; Practice payments to pharmacies dispensing at least 1,100 items per month in the community pharmacy contract for 2005-2006; Summary of pharmaceutical cost-containment measures in the UK

Abstract

National pharmaceutical pricing and reimbursement is a complex and ever-changing area. In a rapidly globalising market it is essential that executives are briefed on the regulatory systems that determine the way in which your company operates and sells its products.

The Guide to Pharmaceutical Pricing and Reimbursement Systems: Western Europe is a straightforward guide to the pricing and reimbursement mechanisms in the major European markets.

The Guide will:

save you time by concisely explaining the key elements of pricing and reimbursement regulation
offer insight into latest policies and the political environment
increase your knowledge of the ways in which governments influence and control the pharmaceutical industry

Each country section has the following headings:

Summary
How is the healthcare system structured?
What size is the pharmaceutical market?
Are pharmaceuticals taxed?
How are drug prices set?
How are prices changed?
How are drugs reimbursed?
Is there a payback arrangement?
Are hospital sales controlled?
Are OTC prices regulated?
How are pharmaceutical costs controlled?
How are generic drugs priced?
What are wholesale/pharmacy margins?
Is parallel trade influential?
What to look out for
Abbreviations
Useful Contacts

Key features of this unique book

Easy to use

Standardised headings and full indexing allow you to access the relevant information quickly

Well researched

Extensive use of primary and secondary sources makes the book extremely comprehensive

Up to date

Impending developments are clearly indicated, allowing you to anticipate the changes that will affect you business

Clearly presented

Using a question and answer format, the information is easily digestible

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The Guide to Pharmaceutical Pricing & Reimbursement Systems: Western Europe

Table of Contents

Abstract